Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710315 | 0.83 | MAOA (0.49) | MAOACA1CA2CA4CA7 | |
| SCHEMBL4200330 | 0.81 | MAOA (0.50) | MAOACA1CA2CA4CA7 | |
| SCHEMBL1710889 | 0.80 | MAOA (0.46) | MAOACA1CA2CA4CA7 | |
| SCHEMBL27016849 | 0.79 | MAOA (0.47) | MAOACA1CA2CA4CA7 | |
| SCHEMBL27016721 | 0.79 | MAOA (0.47) | MAOACA1CA2CA4CA7 | |
| SCHEMBL3491068 | 0.77 | SMN1; SMN2 (0.46) | MAOACA2MAPTMAOBALDH1A1 | |
| SCHEMBL98008 | 0.77 | ALDH1A1 (0.48) | MAOAMAOBALDH1A1MAPK1GAA | |
| SCHEMBL31299577 | 0.75 | MAOA (0.59) | MAOACA1CA2CA4CA7 | |
| SCHEMBL100217 | 0.75 | MAOA (0.59) | MAOACA1CA2CA4CA7 | |
| SCHEMBL677696 | 0.75 | MAOA (0.47) | MAOACA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| CN-101006078-A | Gonadotropin releasing hormone receptor antagonists | WYETH CORP (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1758895-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009734-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | GNRHR, GHRHR, LHCGR | MAOA 3516/4885CA1 2136/4885CA2 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.